-
1.发明授权DRUG COMBINATIONS COMPRISING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME 3A4 有权活性化合物结合物，包括：（E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲磺酰基）氨基]嘧啶-5-基]（3R，5S）-3,5-二羟基庚-6- 烯酸和A抑制剂，诱导剂或P450同工酶3A4衬底
公开(公告)号：EP1185274B1
公开(公告)日：2004-11-17
申请号：EP00901264.2
申请日：2000-02-01
发明人： RAZA, Ali , PEARS, John Stuart , HUTCHINSON, Howard Gerard , SCHNECK, Dennis , BABA, Takahiko , TOUCHI, Akira , YAMAGUCHI, Yoshitaka
IPC分类号： A61K31/505 , A61P3/06
CPC分类号： A61K45/06 , A61K31/365
摘要： The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.
-
2.发明公开DRUG COMBINATIONS COMPRISING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME 3A4 有权活性化合物结合物，包括：（E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲磺酰基）氨基]嘧啶-5-基]（3R，5S）-3,5-二羟基庚-6- 烯酸和A抑制剂，诱导剂或P450同工酶3A4衬底
公开(公告)号：EP1185274A1
公开(公告)日：2002-03-13
申请号：EP00901264.2
申请日：2000-02-01
发明人： RAZA, Ali , PEARS, John Stuart , HUTCHINSON, Howard Gerard , SCHNECK, Dennis , BABA, Takahiko , TOUCHI, Akira , YAMAGUCHI, Yoshitaka
IPC分类号： A61K31/505 , A61P3/06
CPC分类号： A61K45/06 , A61K31/365
摘要： The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.
-
3.发明授权USE OF ROSUVASTATIN (ZD-4522) IN THE TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 无效瑞舒伐他汀（ZD-4522）用于治疗杂合家族性高胆固醇USE
公开(公告)号：EP1339409B1
公开(公告)日：2008-05-07
申请号：EP01982623.9
申请日：2001-11-16
申请人： AstraZeneca AB
IPC分类号： A61K31/505 , A61P3/06
CPC分类号： A61K31/505
摘要： The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
-
4.发明公开USE OF ROSUVASTATIN (ZD-4522) IN THE TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 无效瑞舒伐他汀（ZD-4522）用于治疗杂合家族性高胆固醇USE
公开(公告)号：EP1339409A1
公开(公告)日：2003-09-03
申请号：EP01982623.9
申请日：2001-11-16
申请人： AstraZeneca AB
IPC分类号： A61K31/505 , A61P3/06
CPC分类号： A61K31/505
摘要： The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
